Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Revenue (2020 - 2023)

Gain Therapeutics has reported Revenue over the past 4 years, most recently at $55180.0 for Q1 2023.

  • Quarterly results put Revenue at $55180.0 for Q1 2023, up 22.61% from a year ago — trailing twelve months through Dec 2023 was $55180.0 (down 60.62% YoY), and the annual figure for FY2023 was $55180.0, down 60.62%.
  • Revenue for Q1 2023 was $55180.0 at Gain Therapeutics, down from $95102.0 in the prior quarter.
  • Over the last five years, Revenue for GANX hit a ceiling of $95102.0 in Q2 2022 and a floor of $5269.0 in Q1 2021.
  • Median Revenue over the past 4 years was $27345.0 (2021), compared with a mean of $34067.4.
  • Peak annual rise in Revenue hit 1180.67% in 2021, while the deepest fall reached 21.04% in 2021.
  • Gain Therapeutics' Revenue stood at $9139.0 in 2020, then soared by 297.65% to $36341.0 in 2021, then skyrocketed by 161.69% to $95102.0 in 2022, then crashed by 41.98% to $55180.0 in 2023.
  • The last three reported values for Revenue were $55180.0 (Q1 2023), $95102.0 (Q2 2022), and $45006.0 (Q1 2022) per Business Quant data.